News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Deals and strategy
IDEX (IEX) has shown strong performance over the past year with a 47.17% total return, driven by solid revenue and net income. While its share price has risen significantly, analysts still consider it undervalued, with a fair value estimated at $254.50 compared to its last close of $238.94. The company's recent acquisition of Mott is expected to enhance …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides a technical analysis of IDEXX Laboratories Inc (IDXX), focusing on its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock has a momentum score of 3.37, trading between a resistance of 605.29 and support …
IDEX Chief Accounting Officer Lisa Anderson recently sold 385 shares of company stock, totaling $91,857.15, reducing her stake by 8.17%. Despite this insider sale, analysts generally maintain a "Moderate Buy" rating for IDEX with an average target price of $260.80, following strong Q2 earnings …
Lisa Anderson, Senior Vice President at IDEX Corp. (NASDAQ:IEX), sold 385 shares of company stock for $91,859 on August 12, 2026, after acquiring the same number of shares through options exercise. Following the transactions, Anderson directly owns 4,327 shares. The sale occurred while IDEX …
Lisa Anderson, SVP at IDEX Corp., sold 385 shares for $91,859 on August 12, 2026, after acquiring the same number of shares through option exercise. This transaction occurred while IDEX stock is trading near its 52-week high and appears overvalued based on InvestingPro analysis. …
Lisa M. Anderson, SVP, GC, CAO & Corporate Secretary at IDEX Corp (IEX), exercised options for 385 shares at $93.27 each and subsequently sold all 385 shares at a weighted average price of $238.5949 per share. The options were originally granted in 2018 and …
IDEX Corporation (IEX) has received strong buy ratings from analysts, with price targets around $280, indicating a potential upside of 15.20%. The company's fair value has been increased to $254.50, driven by updated assumptions for revenue growth and profit margins. IDEX has also been …
Assenagon Asset Management S.A. significantly reduced its stake in IDEX Corporation, selling 81.9% of its holdings but still retaining shares valued at $5.51 million. Despite this reduction, institutional investors collectively own 97.96% of IDEX, and analysts maintain a "Moderate Buy" consensus rating with an …
IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected …
Sharemaestro market context Price above Trend Line 52 weeks -13.7% · Next-week setup negative 32.7%This article details an SEC Form 144 filing by IDEX Corp /DE/ (IEX) on August 12, 2026. The filing indicates a proposed sale of 385 common shares with an aggregate market value of $91831.96, acquired through a stock option release on the same date. …
Mizuho has upgraded IDEX Corp (NYSE:IEX) to Outperform from Neutral and raised its price target to $280, citing the company's successful portfolio repositioning towards higher-growth, less-cyclical markets. This shift is leading to stronger organic growth and improved revenue visibility, with orders accelerating significantly in …
Barclays has updated its price target for IDEXX Laboratories (IDXX), lowering it to $710 from the previous $800. Despite this adjustment, the firm has decided to maintain its Overweight rating on the stock. This indicates a continued positive outlook on the company's performance, even …
IDEXX Laboratories Inc. has launched the Catalyst proBNP Test, an in-clinic diagnostic tool for heart disease in cats and dogs. This test measures the NT-proBNP biomarker, providing rapid quantitative results to veterinarians for screening, diagnosis, and monitoring of cardiac conditions. The test will be …
IDEX Corp. (IEX) saw its stock rally 1.73% to $237.31 on a tough trading day for the broader market, outperforming the S&P 500 and Dow Jones Industrial Average, which both fell. The company's stock closed 2.66% below its 52-week high reached on July 29th. …
IDEXX Laboratories Inc. (IDXX) stock fell 1.53% on Tuesday, closing at $586.64, despite a general downturn in the stock market. The S&P 500 Index and Dow Jones Industrial Average also saw declines of 0.32% and 0.34%, respectively. The company's stock is now 23.81% below …
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike Erickson Chief Financial Officer - Andrew Emerson Vice President, Investor Relations - John Ravis Full Conference Call Transcript Operator: Good morning, …
Sharemaestro market context Price above Trend Line 52 weeks -13.7% · Next-week setup negative 32.7%IDEXX Laboratories, Inc. has launched the Catalyst™ proBNP Test, a new dual-species, in-clinic test for NT-proBNP, expanding its cardiac diagnostic capabilities. This test provides rapid, accurate quantitative cardiac assessment for cats and dogs directly at the point of care, addressing a significant need in …
Sharemaestro market context Price above Trend Line 52 weeks -13.7% · Next-week setup negative 32.7%IDEXX Laboratories has introduced the Catalyst proBNP Test, designed for in-clinic assessment of cardiac disease in animals. This launch is expected to enhance veterinary diagnostics by providing rapid and accurate results. The company, a leader in veterinary diagnostics, continues to innovate in the animal …
IDEXX Laboratories has launched the Catalyst™ proBNP Test, a new in-clinic diagnostic tool for heart disease in cats and dogs. This dual-species test provides quantitative NT-proBNP results in minutes, allowing veterinarians to assess cardiac health and make informed treatment decisions faster. The test expands …
IDEXX Laboratories Inc. (IDXX) saw its stock rally by 1.55% to $595.76 on Monday, performing strongly despite an overall poor trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both experienced declines. IDEXX Laboratories Inc. is currently trading …
Contravisory Investment Management Inc. recently acquired 5,194 shares of IDEX Corporation (NYSE: IEX) during the second quarter, valued at approximately $1.18 million. IDEX exceeded quarterly earnings expectations with $2.32 EPS and $920.6 million in revenue, leading analysts to maintain a "Moderate Buy" rating and …
Seilern Investment Management Ltd increased its stake in IDEXX Laboratories, Inc. by 20.7% in the second quarter, purchasing an additional 16,729 shares. The firm now holds 97,560 shares valued at approximately $51.4 million, making IDEXX its fifth-largest position. IDEXX Laboratories reported strong quarterly results, …
This article provides comprehensive 30-year financial data for IDEXX Laboratories Inc (HAM:IX1), including growth rates for revenue, EPS, EBIT, EBITDA, and free cash flow. It details key financial metrics such as Market Cap, Enterprise Value, PE Ratio, PB Ratio, and GF Score, offering an …
IDEXX Laboratories reported a 9% organic revenue growth in Q2 2026 and has subsequently increased its EPS guidance to $14.69–14.94, driven by strong demand for its veterinary diagnostic products. While growth in the US market is decelerating, significant long-term potential is seen in international …
This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, key financial statistics, historical performance, and analyst ratings. It details the company's operations in animal diagnostics, water quality, and veterinary software, and compares its performance to benchmarks like …
Aurora Investment Managers LLC. has acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX), purchasing 4,638 shares valued at approximately $2.44 million. This investment makes IDEXX Laboratories the 21st largest position in Aurora Investment Managers' portfolio, representing 1.5% of its total investments. The article …
This article provides an earnings forecast for IRIDEX Corp (IRIX), indicating a current earnings forecast score of 8.00 and a "Buy" rating based on one analyst. It details future revenue and EPS expectations, with an anticipated next-quarter revenue of $12.98 million and an EPS …
DA Davidson has adjusted its price target on IDEX (IEX) to $240 from $230. The company currently holds an average analyst rating of overweight, with a mean price target across analysts of $250.92.
Search by ticker symbol or company name and select a result to open its chart.